Table 2.
Safety and toxicity profiles
| PC (n=46) |
P (n=45) |
PC+P (n=91) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Gr 1-2 | Gr ≥ 3 | Total | Gr 1-2 | Gr ≥ 3 | Total | Gr 1-2 | Gr ≥ 3 | Total | |
| Fatigue | 14 | 0 | 14 | 10 | 1 | 11 | 24 | 1 | 25 |
| GI toxicity | 22 | 4 | 26 | 18 | 0 | 18 | 40 | 4 | 44 |
| Bleeding or thrombocytopenia | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 2 |
| Neutropenia | 1 | 2 | 3 | 0 | 3 | 3 | 1 | 5 | 6 |
| Neurotoxicity | 8 | 0 | 8 | 2 | 0 | 2 | 10 | 0 | 10 |
| Skin and alopecia | 5 | 0 | 5 | 8 | 0 | 8 | 13 | 0 | 13 |
| Myalgia and arthralgia | 2 | 0 | 2 | 4 | 0 | 4 | 6 | 0 | 6 |
| Othersa) | 25 | 8 | 33 | 27 | 5 | 32 | 52 | 13 | 65 |
PC, pemetrexed plus cisplatin combination followed by maintenance pemetrexed; P, pemetrexed only; Gr, grade; GI, gastrointestinal.
a)
Others include headache, insomnia, dyspnea and pain on other sites than muscles and joints.